OrthoPediatrics (NASDAQ:KIDS) Shares Down 3.7% – Time to Sell?

OrthoPediatrics Corp. (NASDAQ:KIDS) was down 3.7% during mid-day trading on Friday . The company traded as low as $25.23 and last traded at $25.25. 104,364 shares changed hands during mid-day trading, a decline of 38% from the average session volume of 168,822 shares. The stock had previously closed at $26.23.

Analyst Ratings Changes

A number of research analysts recently weighed in on KIDS shares. Piper Sandler restated an “overweight” rating and set a $25.00 target price (up from $22.00) on shares of OrthoPediatrics in a research note on Wednesday, August 5th. TD Cowen reissued a “buy” rating on shares of OrthoPediatrics in a report on Monday, June 15th. Weiss Ratings raised OrthoPediatrics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, August 5th. Canaccord Genuity Group set a $25.00 price objective on OrthoPediatrics in a research note on Friday, April 24th. Finally, BTIG Research increased their target price on OrthoPediatrics from $24.00 to $29.00 and gave the stock a “buy” rating in a research report on Thursday. Nine equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $26.44.

OrthoPediatrics Stock Performance

The company has a market capitalization of $664.50 million, a P/E ratio of -15.15 and a beta of 0.98. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.17 and a current ratio of 4.78. The business’s fifty day simple moving average is $20.70 and its 200-day simple moving average is $18.36.

OrthoPediatrics (NASDAQ:KIDS) last issued its quarterly earnings data on Tuesday, August 4th. The company reported ($0.26) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.04. The firm had revenue of $70.51 million during the quarter, compared to analyst estimates of $68.21 million. OrthoPediatrics had a negative return on equity of 8.10% and a negative net margin of 15.72%. As a group, equities analysts anticipate that OrthoPediatrics Corp. will post -1.14 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Millennium Management LLC grew its holdings in OrthoPediatrics by 48.0% during the 4th quarter. Millennium Management LLC now owns 1,396,495 shares of the company’s stock valued at $24,802,000 after purchasing an additional 452,840 shares during the last quarter. BlackRock Inc. purchased a new position in shares of OrthoPediatrics during the second quarter valued at approximately $24,347,000. Vanguard Group Inc. boosted its position in shares of OrthoPediatrics by 1.1% during the third quarter. Vanguard Group Inc. now owns 961,330 shares of the company’s stock valued at $17,813,000 after buying an additional 10,927 shares during the period. Granahan Investment Management LLC grew its stake in shares of OrthoPediatrics by 35.1% during the first quarter. Granahan Investment Management LLC now owns 896,741 shares of the company’s stock valued at $14,231,000 after buying an additional 232,760 shares during the last quarter. Finally, Wasatch Advisors LP grew its stake in shares of OrthoPediatrics by 56.6% during the second quarter. Wasatch Advisors LP now owns 515,677 shares of the company’s stock valued at $9,865,000 after buying an additional 186,357 shares during the last quarter. Institutional investors own 69.05% of the company’s stock.

OrthoPediatrics Company Profile

OrthoPediatrics Corp., founded in 2007 and headquartered in Warsaw, Indiana, is a medical device company dedicated exclusively to providing orthopedic solutions for children. The company focuses on developing, manufacturing and marketing a broad portfolio of implants and instruments designed to address a wide range of pediatric conditions, including trauma, deformity correction, spine disorders and sports injuries.

The company’s product lines include locking plates and screws for upper and lower extremity reconstruction, intramedullary nails for femur and tibia stabilization, and specialized systems such as the MAGEC Magnetic Growth Rod for treatment of early-onset scoliosis.